Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
147M
-
Number of holders
-
195
-
Total 13F shares, excl. options
-
108M
-
Shares change
-
+2.05M
-
Total reported value, excl. options
-
$2.48B
-
Value change
-
+$45.5M
-
Put/Call ratio
-
9.2
-
Number of buys
-
114
-
Number of sells
-
-64
-
Price
-
$23.04
Significant Holders of Denali Therapeutics Inc. - COMMON STOCK (DNLI) as of Q1 2023
219 filings reported holding DNLI - Denali Therapeutics Inc. - COMMON STOCK as of Q1 2023.
Denali Therapeutics Inc. - COMMON STOCK (DNLI) has 195 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 108M shares
of 147M outstanding shares and own 73.3% of the company stock.
Largest 10 shareholders include BAILLIE GIFFORD & CO (15.4M shares), VANGUARD GROUP INC (10.1M shares), BlackRock Inc. (9.47M shares), Temasek Holdings (Private) Ltd (6.9M shares), Crestline Management, LP (6.41M shares), WELLINGTON MANAGEMENT GROUP LLP (5.2M shares), STATE STREET CORP (4.59M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.54M shares), Flagship Pioneering Inc. (2.62M shares), and ARCH Venture Management, LLC (2.57M shares).
This table shows the top 195 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.